Effect of Rosuvastatin Therapy on Troponin I Release Following Percutaneous Coronary Intervention in Nonemergency Patients (from the TIP 3 Study)

Josef Veselka(Universitat Autònoma de Barcelona), David Zemánek, Pavol Tomašov(Charles University), Marian Branny(Nemocnice Podlesí), Martin Studenčan(National Institute of Cardiovascular Diseases), David Tesař(Charles University), Martin Matějovič(Charles University), Hana Brůhová(Charles University), Petr Hájek(University Hospital in Motol)

The American Journal of Cardiology

November 9, 2013

10.1016/j.amjcard.2013.10.026

Cited by 10

Related Papers

Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trial

|The Lancet|2020|1.2k

Effect of Intra-arrest Transport, Extracorporeal Cardiopulmonary Resuscitation, and Immediate Invasive Assessment and Treatment on Functional Neurologic Outcome in Refractory Out-of-Hospital Cardiac Arrest

|JAMA|2022|674

Long‐term health outcome and mortality evaluation after invasive coronary treatment using drug eluting stents with or without the IVUS guidance. Randomized control trial. HOME DES IVUS

|Catheterization and Cardiovascular Interventions|2009|190

Long-term survival after alcohol septal ablation for hypertrophic obstructive cardiomyopathy: a comparison with general population

|European Heart Journal|2014|106

A FTO variant and risk of acute coronary syndrome

|Clinica Chimica Acta|2010|65